AzTrials
AzTrials

EclampsiaTiPERNCT06219109

Pulmonary Edema Resolution in Severe Preeclampsia and Eclampsia

An observational study of Eclampsia and Severe Pre-eclampsia, run by Doctors with Africa - CUAMM at 1 site in Sierra Leone.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Patients with severe preeclampsia or eclampsia suffer from pulmonary complications. Accurate assessment of patients with pulmonary involvement using lung ultrasound (LUS) and echocardiography could lead to earlier detection of pre eclampsia and eclampsia associated pulmonary oedema, ARDS (acute respiratory distress… Read more about this study

Who is it for?
Any age, women only
Conditions the study is for
Eclampsia, Severe Pre-eclampsia
How many people
55 participants
Where
1 siteSierra Leone
Study dates
8 May 2023to 2 Apr 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients hospitalized at PCMH with severe preclampsia and eclampsia will be enrolled if the applicable inclusion and exclusion criteria are met

Who may be able to join

  • All patients with severe pre-eclampsia or eclampsia admitted to hospital Princess Christian Maternity Hospital

Who cannot join

  • Patients with chronic hypertensive disorders
  • Lung ultrasound not feasible, e.g., due to electricity breakdown, or absence of the trained sonographer or presence of subcutaneous emphysema,

Trial locations and contacts

1 site in 1 country.

Sierra Leone1 site, 1 recruiting
  • Princess Christian Maternity Hospital

    Freetown

    Momoh Sitta Turay, +23278682722, m.turay@cuamm.org

    Recruiting

Other trials in Sierra Leone

About this study

Official title: SeveriTy of Pulmonary Edema and Timing of Resolution in Patients With Severe Pre-eclampsia and Eclampsia (TIPER): A Physiological and Sonographic Prospective Observational Study

Patients with severe preeclampsia or eclampsia suffer from pulmonary complications. Accurate assessment of patients with pulmonary involvement using lung ultrasound (LUS) and echocardiography could lead to earlier detection of pre eclampsia and eclampsia associated pulmonary oedema, ARDS (acute respiratory distress syndrome) and other pulmonary complications. here is currently limited evidence regarding the features, severity, aetiology and history of pulmonary oedema in this group of patients Data from this prospective observational study will facilitate the early recognition of pre-eclamptic and eclamptic patients with pulmonary involvement to implement optimal triage and early therapeutic choices in a limited resource setting (diuretics, escalation to non invasive or invasive ventilation, referral to HDU (High dependency unit) or ICU, dialysis) and potentially reduce unfavorable outcomes.

Read the detailed description

Background - Maternal mortality from treatable causes concerning the critical care domain in low- income countries remains strikingly high. Maternal mortality in Sierra Leone is the highest in the world with 1,360 deaths per 100,000 born alive. The burden of obstetric-related critical care morbidity is also extremely high. In high-income countries less than 2% of intensive care unit admissions relate to obstetric illnesses, but these rise to 10% in resource-limited settings. Pre-eclampsia/eclampsia are hypertensive disorders of pregnancy, one of the 3 leading causes of maternal morbidity and mortality worldwide. Respiratory distress and pulmonary oedema are known complications of preeclampsia-eclampsia and their insurgence is a hallmark of severe disease. Pulmonary oedema is reported as a complication in 2.9% of patients with preeclampsia-eclampsia. Pulmonary involvement is associated with worse maternal and perinatal outcomes. Incidence is significantly higher in low income countries, rising to 12% due to poorer prenatal care and access to hospital care, and suboptimal diagnostic and management processes .

Aim - The primary aim is to describe the frequency of lung ultrasound consistent with pulmonary oedema and the timing of resolution after delivery.

Secondary aims include the assessment of the frequency of acute respiratory failure, other LUS findings beyond pulmonary edema, the assessment of oxygenation, the use of respiratory organ support strategies, assessment of cardiac function, and quantification of major direct/ indirect obstetric complications and of perinatal complications.

Hypothesis -

  1. A high proportion (>20%) of patients show LUS signs consistent with pulmonary edema before delivery.
  2. There is incomplete resolution of both clinical and ultrasound signs after in the 72 hours after delivery.

Setting - Princess Christian Maternity Hospital, Freetown, Sierra Leone Population - Female subjects, hospitalized with severe preeclampsia or eclampsia Methods - Single centre, prospective, cohort study of patients with severe pre-eclampsia and eclampsia. The expected duration of study is 1 year. All patients with suspected severe pre-eclampsia or eclampsia will undergo screening upon admission to HDU and the Eclamptic ward. Eligible patients will undergo a systematic clinical and LUS examination, straight after admission (before delivery). Clinical examination will focus on signs of respiratory, neurologic and cardiac failure. Lung ultrasound will be performed using a Butterfly ultrasound probe (Butterfly, USA). Lung ultrasound will be performed using the validated 12-region method. As heart failure is a common finding in preeclamptic women, echocardiography performed with a cardiac sector probe, will enable real-time assessment of maternal cardiac contractility and cardiac output. The same clinical, LUS and echocardiographic assessment will be repeated between 24 h to 72 h (after delivery). Whenever the pre-delivery timepoint is not feasible due to late arrival, emergency scenario or postpartum onset, the after delivery examination only will be performed.

Keywords
Eclampsia, Preeclampsia, Lung ultrasound scan, Pulmonary oedema, Respiratory distress
Medical subject headings
Eclampsia, Pre-Eclampsia, Pulmonary Edema, Dyspnea

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Frequency of LUS consistent with pulmonary edema

    Frequency endpoint: proportion of patients with a LUS positive for pulmonary edema Severity: LUS aeration score

    Measured: during hospital stay, average of 1 month

  2. Timing of resolution after delivery

    Categorical: Fraction of patients with improvement or resolution of LUS findings.

    Numerical: delta LUS score between T1 and T2

    Measured: during hospital stay, average of 1 month

Secondary outcomes (8)
  1. Frequency of acute respiratory failure in patients with Severe Pre eclampsia and in patients with Eclampsia

    Proportion of patients with acute respiratory failure

    Measured: during hospital stay, average of 1 month

  2. Frequency of other LUS findings

    Proportion of patients with

    • consolidations
    • isolated pleural effusion
    • minor LUS findings

    Measured: during hospital stay, average of 1 month

  3. Frequency of organ support strategies

    Fraction of patients that receive oxygen and/or CPAP (Continuous Positive Airway Pressure) and/or mechanical ventilation

    Measured: during hospital stay, average of 1 month

  4. Frequency of patients with abnormal cardiac function

    Defined as low cardiac index measured by ultrasound

    Measured: during hospital stay, average of 1 month

  5. Oxygenation assessment

    SpO2 (peripheral capillary oxygen saturation) to FiO2 (fraction of inspired oxygen) ratio

    Measured: during hospital stay, average of 1 month

  6. Frequency of Major Direct Obstetric Complications (MDOCs)

    Fraction of patients with at least one additional MDOC (antepartum hemorrhage, postpartum hemorrhage, sepsis, uterine rupture, obstructed labour)

    Measured: during hospital stay, average of 1 month

  7. Frequency of Indirect Obstetric complications

    Fraction of patients with at least one among stroke, severe malaria, acute kidney injury and cardiac insufficiency.

    Measured: during hospital stay, average of 1 month

  8. Frequency of perinatal complications

    Intra uterine fetal death (IUFD), Apgar score, Admission to special care baby unit (SCBU)

    Measured: during hospital stay, average of 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jan 2024
  2. Study start8 May 2023
  3. Primary completion1 Apr 2024 (estimated)
  4. Study completion2 Apr 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
55 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06219109
Sponsor's protocol ID
Cuamm_02/23
Acronym
TiPER
Status last verified
Jan 2024
First submitted
8 Sep 2023
Last updated
23 Jan 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Eclampsia and Severe Pre-eclampsia, run by Doctors with Africa - CUAMM at 1 site in Sierra Leone.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sierra Leone. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Serena Crisci (+393387237228, serena.crisci@virgilio.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Frequency of LUS consistent with pulmonary edema (time frame: during hospital stay, average of 1 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in